News & Updates
Filter by Specialty:
Show Multimedia Only
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
byAudrey Abella
The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo
22 Oct 2025
byStephen Padilla
Treatment with the Janus kinase (JAK) 1 inhibitor povorcitinib results in significant repigmentation of the body and face in adult patients with extensive nonsegmental vitiligo (NSV), with an acceptable safety profile, through 52 weeks, reports a phase II study.
